Pitavastatin

19 interactions 1 explained in plain English
Also sold as: Livalo Livalo® Nikita Zypitamag Zypitamag®
About Pitavastatin

Pitavastatin is used together with diet, weight-loss, and exercise to reduce the amount of fatty substances such as low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood and to increase the amount of high-density lipoprotein (HDL) cholesterol ('good cholesterol') in adults. Pitavastatin is also use… Read the full Pitavastatin drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Cyclosporine Injection Cyclosporine Ophthalmic Leniolisib Niacin Leflunomide Letermovir Injection
2 Contraindicated 14 Major 3 Moderate
All (19) Contraindicated (2) Major (14) Moderate (3)

Contraindicated

Pitavastatin Cyclosporine Injection Atopica Increased pitavastatin exposure and increased risk of myopathy and rhabdomyolysis Details Pitavastatin Cyclosporine Ophthalmic Cequa Increased pitavastatin exposure and increased risk of myopathy and rhabdomyolysis Details

Major

Pitavastatin Colchicine Colcrys Explained An increased risk of myopathy or rhabdomyolysis Details Pitavastatin Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Pitavastatin Daptomycin Cubicin Increased risk of myopathy or rhabdomyolysis Details Pitavastatin Daptomycin Injection Cubicin Increased risk of myopathy or rhabdomyolysis Details Pitavastatin Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Pitavastatin Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Pitavastatin Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Pitavastatin Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Pitavastatin Gemfibrozil Lopid Increased pitavastatin plasma concentrations and increased risk of myopathy or rhabdomyolysis Details Pitavastatin Leflunomide Arava Increased exposure of OATP1B1/1B3 substrate Details Pitavastatin Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Pitavastatin Letermovir Injection Prevymis Increased pitavastatin exposure and an increased risk for myopathy and rhabdomyolysis Details Pitavastatin Midostaurin Rydapt Increased OATP1B1 substrate exposure Details Pitavastatin Niacin Endur-Acin Increased risk of myopathy and rhabdomyolysis Details

Moderate

Pitavastatin Encorafenib Braftovi Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Pitavastatin Fostemsavir Rukobia Increased exposure of the HMG-CoA reductase inhibitor Details Pitavastatin Lanthanum Fosrenol® Reduced statin bioavailability Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.